Gadofosveset

Drug Profile

Gadofosveset

Alternative Names: Ablavar; AngioMARK; Gadofosveset-trisodium; MS 325; MS 32520; Vasovist; ZK 236018

Latest Information Update: 25 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Massachusetts General Hospital
  • Developer EPIX Pharmaceuticals
  • Class Lanthanoid series elements; Organometallic compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 20 Nov 2009 The CHMP of the European Medicines Agency makes recommendations to minimise the risk of nephrogenic systemic fibrosis
  • 08 Oct 2009 Adverse events data from post-marketing review released by Lantheus Medical Imaging
  • 07 Apr 2009 Gadofosveset out-licensed to Lanthus Medical Imaging in the US, Puerto Rico, Canada and Australia ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top